| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 328785 | Journal of Substance Abuse Treatment | 2015 | 11 Pages |
•A prospective cohort of people who tamper with pharmaceutical opioids was formed to provide essential data on the impact of Reformulated OxyContin® in Australia.•Heterogeneity in the patterns and clinical correlates of opioid use suggest that Reformulated OxyContin® will have different impacts in different groups within the cohort.•Targeted health interventions are essential to reduce the associated harms associated with tampering.•Many participants obtained opioids via prescription, presenting opportunity for intervention.
AimsTo describe the methods and baseline characteristics of a cohort of people who tamper with pharmaceutical opioids, formed to examine changes in opioid use following introduction of Reformulated OxyContin®.MethodsParticipants were 606 people from three Australian jurisdictions who reported past month injecting, snorting, chewing or smoking of a pharmaceutical opioid and had engaged in these practices at least monthly in the past 6 months. Baseline interviews were conducted prior to introduction of Reformulated OxyContin® in April 2014. Patterns of opioid use and cohort characteristics were examined according to whether participants were prescribed opioid medications, or exclusively used diverted medication.ResultsThe cohort reported high levels of moderate/severe depression (61%), moderate/severe anxiety (43%), post-traumatic stress disorder (42%), chronic pain or disability (past 6 months, 54%) and pain (past month, 47%). Lifetime use of oxycodone, morphine, opioid substitution medications and codeine were common. Three-quarters (77%) reported ICD-10 lifetime pharmaceutical opioid dependence and 40% current heroin dependence. Thirteen percent reported past year overdose, and 70% reported at least one past month opioid injection-related injury or disease. The cohort displayed complex clinical profiles, but participants currently receiving opioid substitution therapy who were also prescribed other opioids particularly reported a wide range of risk behaviors, despite their health service engagement.ConclusionsFindings highlight the heterogeneity in the patterns and clinical correlates of opioid use among people who tamper with pharmaceutical opioids. Targeted health interventions are essential to reduce the associated harms.
